LSE:BXP
Beximco Pharmaceuticals Limited · LSE · Healthcare · GBP · FY for 2024
Figures on this page computed 2026-11-08 09:30 UTC
Last close
n/aGBp
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
7.6xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
- Computed from the filing for 2024
12.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
13.1%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
13.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
0.13Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2024
- Sales1.70x
Its own average over 10 years, 26.08B.
- Profit1.64x
Its own average over 10 years, 3.55B.
- Free cash flow4.94x
Its own average over 10 years, 1.24B.
- Debt0.70x
Its own average over 10 years, 8.65B.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 4.94 times.
It reports in BDT and trades in GBP. Nothing on this page is converted between the two.
The filed years, as a table
10Each line is 100 at 2014-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2014-12-31 | 100.0 | 100.0 | 100.0 |
| 2015-12-31 | 179.6 | 127.9 | 100.0 |
| 2017-06-30 | 138.4 | 145.7 | 100.0 |
| 2018-06-30 | 158.1 | 166.0 | 100.0 |
| 2019-06-30 | 203.6 | 198.5 | 100.0 |
| 2020-06-30 | 228.5 | 230.0 | 100.0 |
| 2021-06-30 | 263.2 | 335.5 | 100.0 |
| 2022-06-30 | 309.4 | 335.2 | 100.0 |
| 2023-06-30 | 350.4 | 301.9 | 100.0 |
| 2024-06-30 | 396.1 | 381.4 | 100.0 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- BDT
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- BDT
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- BDT
Figures behind the shape
Growth
14.2%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate14.2%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
Five-year EPS growth rate14.0%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
One-year change in net income26.3%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
Returns on capital
12.7%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capital12.7%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
Return on equity12.2%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Return on assets8.4%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Margins
44.2%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin44.2%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Operating margin19.5%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Net margin13.1%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Free cash flow margin13.8%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Price
7.6xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earnings7.6x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
- Computed from the filing for 2024
Price to book0.9x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
- Computed from the filing for 2024
- computed
- Computed from the filing for 2024
EV to EBITDA4.7x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
Price to sales ratio1.0x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
- Computed from the filing for 2024
- Computed from the filing for 2024
Safety
0.13safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equity0.13
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Current ratio2.18
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Interest coverage7.5x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
Altman Z-Score3.48
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
What it pays out
27.2%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
Payout ratio27.2%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
Dividend cover ratio3.9x
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.